Semaglutide, the active ingredient in Ozempic, and other drugs in the same class have revolutionized the treatment of obesity and type 2 diabetes. Now, a clinical trial suggests the medicines can treat type 1 diabetes, as well.
The trial results, published June 23 in the journal NEJM Evidence, suggest semaglutide can improve blood sugar levels and induce weight loss in people with type 1, potentially introducing a new drug that could be used along with insulin to manage the disease.
